The reduced expression and function of voltage-dependent potassium (KV) channels have been involved in the pathogenesis of hypoxia-induced pulmonary hypertension (HPH), leading to pulmonary vasoconstriction and vascular remodeling, while the upregulation of KV channels is of therapeutic significance for pulmonary hypertension. Beraprost sodium (BPS) has been shown to be effective in patients with pulmonary hypertension. However, the effect of BPS on O2-sensitive KV channels in pulmonary artery smooth muscle cells (PASMCs) remains unclear. In the present study, the effect of BPS on rats with HPH was observed, and the influence of BPS on the expression and function of O2-sensitive KV channels in PASMCs was investigated. The results revealed that BPS reduced mean pulmonary artery pressure, suppressed right ventricular hypertrophy, and attenuated the remodeling of pulmonary arteries in rats exposed to discontinuous hypoxia for 4 weeks (8 h/day). This was accompanied with the significantly upregulated expression of KV channel α-subunits (KV1.2, KV1.5 and KV2.1) and O2-sensitive voltage-gated K+ (KV) channel current (IK(V)) in small pulmonary arteries in HPH model rats, as well as in hypoxia-induced PASMCs. Furthermore, in vitrostudies have revealed that the upregulation of BPS on O2-sensitive KV channels was significantly inhibited after treatment with prostaglandin E2 receptor subtype EP4 antagonist GW627368X. Taken together, these results suggest that BPS attenuates the development of HPH through the upregulation of O2-sensitive KV channels, which was probably via the EP4 receptor-related pathway.

1.
Cuttica
MJ
.
Pulmonary hypertension associated with lung diseases and hypoxemia
.
Heart Fail Rev
.
2016
May
;
21
(
3
):
299
308
.
[PubMed]
1382-4147
2.
Xu
XQ
,
Jing
ZC
.
High-altitude pulmonary hypertension
.
Eur Respir Rev
.
2009
Mar
;
18
(
111
):
13
7
.
[PubMed]
0905-9180
3.
Humbert
M
,
Lau
EM
,
Montani
D
,
Jaïs
X
,
Sitbon
O
,
Simonneau
G
.
Advances in therapeutic interventions for patients with pulmonary arterial hypertension
.
Circulation
.
2014
Dec
;
130
(
24
):
2189
208
.
[PubMed]
0009-7322
4.
Platoshyn
O
,
Yu
Y
,
Golovina
VA
,
McDaniel
SS
,
Krick
S
,
Li
L
, et al.
Chronic hypoxia decreases K(V) channel expression and function in pulmonary artery myocytes
.
Am J Physiol Lung Cell Mol Physiol
.
2001
Apr
;
280
(
4
):
L801
12
.
[PubMed]
1040-0605
5.
Boucherat
O
,
Chabot
S
,
Antigny
F
,
Perros
F
,
Provencher
S
,
Bonnet
S
.
Potassium channels in pulmonary arterial hypertension
.
Eur Respir J
.
2015
Oct
;
46
(
4
):
1167
77
.
[PubMed]
0903-1936
6.
Burg
ED
,
Remillard
CV
,
Yuan
JX
.
Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: pharmacotherapeutic implications
.
Br J Pharmacol
.
2008
Mar
;
153
(
S1
Suppl 1
):
S99
111
.
[PubMed]
0007-1188
7.
Zhang
S
,
Liu
B
,
Fan
Z
,
Wang
D
,
Liu
Y
,
Li
J
, et al.
Targeted inhibition of survivin with YM155 promotes apoptosis of hypoxic human pulmonary arterial smooth muscle cells via the upregulation of voltage-dependent K⁺ channels
.
Mol Med Rep
.
2016
Apr
;
13
(
4
):
3415
22
.
[PubMed]
1791-2997
8.
Pozeg
ZI
,
Michelakis
ED
,
McMurtry
MS
,
Thébaud
B
,
Wu
XC
,
Dyck
JR
, et al.
In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats
.
Circulation
.
2003
Apr
;
107
(
15
):
2037
44
.
[PubMed]
0009-7322
9.
Vachiéry
JL
.
Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy
.
Adv Ther
.
2011
Apr
;
28
(
4
):
251
69
.
[PubMed]
0741-238X
10.
Coppock
EA
,
Martens
JR
,
Tamkun
MM
.
Molecular basis of hypoxia-induced pulmonary vasoconstriction: role of voltage-gated K+ channels
.
Am J Physiol Lung Cell Mol Physiol
.
2001
Jul
;
281
(
1
):
L1
12
.
[PubMed]
1040-0605
11.
Fan
F
,
Ma
A
,
Guan
Y
,
Huo
J
,
Hu
Z
,
Tian
H
, et al.
Effect of PGE2 on DA tone by EP4 modulating Kv channels with different oxygen tension between preterm and term
.
Int J Cardiol
.
2011
Feb
;
147
(
1
):
58
65
.
[PubMed]
0167-5273
12.
Galiè
N
,
Humbert
M
,
Vachiéry
JL
,
Vizza
CD
,
Kneussl
M
,
Manes
A
, et al.;
Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group
.
Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial
.
J Am Coll Cardiol
.
2002
May
;
39
(
9
):
1496
502
.
[PubMed]
0735-1097
13.
Barst
RJ
,
McGoon
M
,
McLaughlin
V
,
Tapson
V
,
Rich
S
,
Rubin
L
, et al.;
Beraprost Study Group
.
Beraprost therapy for pulmonary arterial hypertension
.
J Am Coll Cardiol
.
2003
Jun
;
41
(
12
):
2119
25
.
[PubMed]
0735-1097
14.
Sakao
S
,
Tanabe
N
,
Kasahara
Y
,
Tatsumi
K
.
Long-term survival of Japanese patients with pulmonary arterial hypertension treated with beraprost sodium, an oral prostacyclin analogue
.
Intern Med
.
2014
;
53
(
17
):
1913
20
.
[PubMed]
0918-2918
15.
Galiè
N
,
Corris
PA
,
Frost
A
,
Girgis
RE
,
Granton
J
,
Jing
ZC
, et al.
Updated treatment algorithm of pulmonary arterial hypertension
.
J Am Coll Cardiol
.
2013
Dec
;
62
(
25
Suppl
):
D60
72
.
[PubMed]
0735-1097
16.
Lai
YJ
,
Pullamsetti
SS
,
Dony
E
,
Weissmann
N
,
Butrous
G
,
Banat
GA
, et al.
Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension
.
Am J Respir Crit Care Med
.
2008
Jul
;
178
(
2
):
188
96
.
[PubMed]
1073-449X
17.
Orie
NN
,
Clapp
LH
.
Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: evidence for Gi/o modulation via EP3 receptors
.
Eur J Pharmacol
.
2011
Mar
;
654
(
3
):
258
65
.
[PubMed]
0014-2999
18.
Fagan
KA
.
Selected Contribution: pulmonary hypertension in mice following intermittent hypoxia
.
J Appl Physiol (1985)
.
2001
Jun
;
90
(
6
):
2502
7
.
[PubMed]
8750-7587
19.
Hartley
SA
,
Kozlowski
RZ
.
Electrophysiological consequences of purinergic receptor stimulation in isolated rat pulmonary arterial myocytes
.
Circ Res
.
1997
Feb
;
80
(
2
):
170
8
.
[PubMed]
0009-7330
20.
Li
YX
,
Run
L
,
Shi
T
,
Zhang
YJ
.
CTRP9 regulates hypoxia-mediated human pulmonary artery smooth muscle cell proliferation, apoptosis and migration via TGF-β1/ERK1/2 signaling pathway
.
Biochem Biophys Res Commun
.
2017
Sep
;
490
(
4
):
1319
25
.
[PubMed]
0006-291X
21.
Archer
SL
,
Wu
XC
,
Thébaud
B
,
Nsair
A
,
Bonnet
S
,
Tyrrell
B
, et al.
Preferential expression and function of voltage-gated, O2-sensitive K+ channels in resistance pulmonary arteries explains regional heterogeneity in hypoxic pulmonary vasoconstriction: ionic diversity in smooth muscle cells
.
Circ Res
.
2004
Aug
;
95
(
3
):
308
18
.
[PubMed]
0009-7330
22.
Christman
BW
,
McPherson
CD
,
Newman
JH
,
King
GA
,
Bernard
GR
,
Groves
BM
, et al.
An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
.
N Engl J Med
.
1992
Jul
;
327
(
2
):
70
5
.
[PubMed]
0028-4793
23.
Del Pozo
R
,
Hernandez Gonzalez
I
,
Escribano-Subias
P
.
The prostacyclin pathway in pulmonary arterial hypertension: a clinical review
.
Expert Rev Respir Med
.
2017
Jun
;
11
(
6
):
491
503
.
[PubMed]
1747-6348
24.
El Yafawi
R
,
Wirth
JA
.
What is the role of oral prostacyclin pathway medications in pulmonary arterial hypertension management?
Curr Hypertens Rep
.
2017
Oct
;
19
(
12
):
97
.
[PubMed]
1522-6417
25.
Ko
EA
,
Han
J
,
Jung
ID
,
Park
WS
.
Physiological roles of K+ channels in vascular smooth muscle cells
.
J Smooth Muscle Res
.
2008
Apr
;
44
(
2
):
65
81
.
[PubMed]
0916-8737
26.
Moudgil
R
,
Michelakis
ED
,
Archer
SL
.
The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension
.
Microcirculation
.
2006
Dec
;
13
(
8
):
615
32
.
[PubMed]
1073-9688
27.
Fantozzi
I
,
Platoshyn
O
,
Wong
AH
,
Zhang
S
,
Remillard
CV
,
Furtado
MR
, et al.
Bone morphogenetic protein-2 upregulates expression and function of voltage-gated K+ channels in human pulmonary artery smooth muscle cells
.
Am J Physiol Lung Cell Mol Physiol
.
2006
Nov
;
291
(
5
):
L993
1004
.
[PubMed]
1040-0605
28.
Shimoda
LA
,
Manalo
DJ
,
Sham
JS
,
Semenza
GL
,
Sylvester
JT
.
Partial HIF-1alpha deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia
.
Am J Physiol Lung Cell Mol Physiol
.
2001
Jul
;
281
(
1
):
L202
8
.
[PubMed]
1040-0605
29.
Mondejar-Parreño
G
,
Callejo
M
,
Barreira
B
,
Morales-Cano
D
,
Esquivel-Ruiz
S
,
Moreno
L
, et al.
miR-1 is increased in pulmonary hypertension and downregulates Kv1.5 channels in rat pulmonary arteries
.
J Physiol
.
2019
Feb
;
597
(
4
):
1185
97
.
[PubMed]
0022-3751
30.
Hoshikawa
Y
,
Voelkel
NF
,
Gesell
TL
,
Moore
MD
,
Morris
KG
,
Alger
LA
, et al.
Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling
.
Am J Respir Crit Care Med
.
2001
Jul
;
164
(
2
):
314
8
.
[PubMed]
1073-449X
31.
Bos
CL
,
Richel
DJ
,
Ritsema
T
,
Peppelenbosch
MP
,
Versteeg
HH
.
Prostanoids and prostanoid receptors in signal transduction
.
Int J Biochem Cell Biol
.
2004
Jul
;
36
(
7
):
1187
205
.
[PubMed]
1357-2725
32.
Abramovitz
M
,
Adam
M
,
Boie
Y
,
Carrière
M
,
Denis
D
,
Godbout
C
, et al.
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs
.
Biochim Biophys Acta
.
2000
Jan
;
1483
(
2
):
285
93
.
[PubMed]
0006-3002
33.
Whittle
BJ
,
Silverstein
AM
,
Mottola
DM
,
Clapp
LH
.
Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist
.
Biochem Pharmacol
.
2012
Jul
;
84
(
1
):
68
75
.
[PubMed]
0006-2952
34.
Li
HH
,
Hsu
HH
,
Chang
GJ
,
Chen
IC
,
Ho
WJ
,
Hsu
PC
, et al.
Prostanoid EP4 agonist L-902,688 activates PPARγ and attenuates pulmonary arterial hypertension
.
Am J Physiol Lung Cell Mol Physiol
.
2018
Mar
;
314
(
3
):
L349
59
.
[PubMed]
1040-0605
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.